Price Chart

Profile

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
URL https://www.savarapharma.com
Investor Relations URL https://savarapharma.com/investors/events-presentations/
HQ State/Province Pennsylvania
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 12, 2025 (est.)
Last Earnings Release May. 13, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
URL https://www.savarapharma.com
Investor Relations URL https://savarapharma.com/investors/events-presentations/
HQ State/Province Pennsylvania
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 12, 2025 (est.)
Last Earnings Release May. 13, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A